Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML

21 Dec 2021

Abstract excerpt

Evidence suggests that combining immunotherapy with hypomethylating agents may enhance antitumor activity. This phase 2 study investigated the activity and safety of durvalumab, a programmed death-ligand 1 (PD-L1) inhibitor, combined with azacitidine for patients aged ≥65 years with acute myeloid leukemia (AML), including analyses to identify biomarkers of treatment response. Patients were randomized to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to CAR-T cell therapy research
Share to Histone Deacetylase Inhibitors Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34933333
DOI: 10.1182/bloodadvances.2021006138

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AMLPMID 34933333Read ↗

A randomized phase II/III study of ‘novel therapeutics’ versus azacitidine in newly diagnosed patients with acute myeloid leukemia (AML), high-risk myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML), age 60 or older: a report of the comparison of azacitidine and nivolumab to azacitidine: SWOG S1612Semantic proximity Read ↗

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance).Semantic proximity Read ↗

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First RemissionSemantic proximity Read ↗

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.Semantic proximity Read ↗

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemiaSemantic proximity Read ↗

Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemia.Semantic proximity Read ↗

Multicenter, Phase II Study of Decitabine for the First-Line Treatment of Older Patients With Acute Myeloid LeukemiaSemantic proximity Read ↗

Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia.Semantic proximity Read ↗

A precision medicine approach to management of acute myeloid leukemia in older adults.Semantic proximity Read ↗

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity Read ↗

Translational Research on Azacitidine Post- Remission Therapy of Acute Myeloid Leukemia in Elderly Patients (QOL-ONE Trans-2)Semantic proximity Read ↗

Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.